You can buy Repodx at the lowest price in the online pharmacy Nextgen.ooo . Repotrectinib is a next-generation tyrosine kinase inhibitor (TKI) specifically designed to address resistance in the treatment of non-small cell lung cancer (NSCLC), particularly due to mutations in the ROS1 gene. ROS1 mutations are one of the identified oncogenic drivers of NSCLC, and the ROS1 G2032R mutation is responsible for 50-60% of resistance to crizotinib.
 
Repotrectinib has a compact macrocyclic structure that limits adverse interactions with resistance mutation hotspots and targets mutations at the solvent front.Although resistance has been reported to several TKIs, including crizotinib, lorlatinib, taletrectinib, and entrectinib, there have been no cases of resistance to repotrectinib. On November 15, 2023, the FDA approved repotrectinib, under the brand name Augtyro, for the treatment of locally advanced or metastatic ROS1-positive NSCLC. This approval is based on favorable results from the TRIDENT-1 trial, where the objective response rate was 79% in TKI-naive patients and 38% in TKI-experienced patients.